Glutathione administration against cisplatin-induced nephrotoxicity does not modify its cytotoxic activity: An experimental study in mice

Oncology Reports

Volumn 4, Issue 5, 1997, Pages 1089-1091

  Sastre, J ^a   Diaz Rubio, E ^a   Cifuentes, L ^a   Blanco, J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cisplatin; Cytotoxic activity; Glutathione

Indexed keywords

CISPLATIN; GLUTATHIONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0030794226     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Arrick BA and Nathan CF: Glutathione metabolism as a determinant of therapeutic efficacy: A review. Cancer Res 44: 4224-4232, 1984.
2. Meijer C, Mulder NH and De Vries EGE: The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. Cancer Treat Rev 17: 389-407, 1990.
3. Zunino F, Tofanetti O, Besati A, et al: Protective effect of reduced glutathione against cis-dichlorodiammmine platinum (II)-induced nephrotoxicity and lethal toxicity. Tumori 69: 105-111, 1983.
4. Hamilton TC, Winker MA, Kovie KG, et al: Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine-sulfoximine mediated glutathione depletion. Biochem Pharmacol 34: 2583-2586, 1985.
5. Hromas RA, Andrews PA, Murphy MP and Burns CP: Glutathione depletion reverses cisplatin resitance in murine L 1210 leukemia cells. Cancer Lett 34: 9-13, 1987.
6. Richon VM, Shulte N and Eastman A: Multiple mechanism of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L 1210 cells. Cancer Res 47: 2056-2061, 1987.
7. Teicher BA, Holden SA, Kelley MJ, et al: Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res 47: 388-393, 1987.
8. Mayer RD, Lee K and Cockett ATK: Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor. Cancer Chemother Pharmacol 20: 207-210, 1987.
9. Sastre J, Diaz-Rubio E, Blanco J and Cifuentes L: Experimental study of the protective effect of glutathione against cisplatin-induced nephrotoxicity. Oncol Rep 3: 1149-1152, 1996.
10. Iwamato Y, Kawano T, Vozumi J, et al: 'Two-route chemotherapy' using high-dose ip cisplatin and iv sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice. Cancer Treat Rep 68: 1367-1373, 1984.
11. Wagner T, Kreft B, Bohlmann G, Schwieder G: Effects of fosfomycin, mesna and sodium thiosulfate on the toxicity and antitumor activity of cisplatin. J Cancer Res Clin Oncol 114: 497-501, 1988.
12. Fontanelli R, Spatti G, Raspagliesi F, Zunino F and Di Re F: A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol 3: 117-121, 1992.
13. Cascinu S, Cordelia L, Del Ferro E, et al: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. J Clin Oncol 13: 26-32, 1995.